Drug intelligence / Profile preview

thiofegastine

Development stage: Preclinical
Lead developer: Air Force Specialty Medical Center

Overview

Based on the clinical trial, thiofegastine is an investigational drug being studied for its safety and efficacy in preventing moderate and severe neutropenia, a common side effect of radiotherapy and chemotherapy in cancer patients. Its mechanism is likely related to stimulating the production of white blood cells to counteract the myelosuppressive effects of cancer treatments.

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on thiofegastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiofegastine.